首页 /药靶模型 /药靶细胞 /激酶靶点 /TFG-NTRK1/BaF3

TFG-NTRK1/BaF3

CBP73193

询 价
留 言
产品描述
产品数据库

I. Introduction
Cell Line Name: TFG-NTRK1/BaF3
Host Cell: Ba/F3
Stability: 16 passages (in-house test, that not means the cell line will be instable beyond the passages we tested.)
Application: Anti-proliferation assay and PD assay
Freeze Medium: 90% FBS+10% DMSO
Complete Culture Medium: RPMI-1640+10% FBS+1 ug/ml puromycin
Mycoplasma Status: Negative
 
II. Background
NTRK1 rearrangements involve the kinase domain of the NTRK1 gene which includes 17 exons located on chromosome 1q21-22 (Alberti et al. 2003). The frequency of NTRK1 fusions in patients with adenocarcinoma histology is 3.3% of cases (3 out of 91 patients; Vaishnavi et al. 2013).
 a In preclinical studies, cell lines expressing MPRIP-NTRK1 or CD74-NTRK1 were inhibited by ARRY-470, a TRKA/B/C inhibitor (Vaishnavi et al. 2013).
 b In preclinical studies, cell lines expressing MPRIP-NTRK1 or CD74-NTRK1 were inhibited by lestaurtinib, a FLT3/TRKA inhibitor (Vaishnavi et al. 2013).
 c A patient with non-small cell lung cancer harboring an MPRIP-NTRK1 fusion mutation was treated with crizotinib, which has activity against TRKA in addition to ALK, MET and ROS1 (Vaishnavi et al. 2013). The patient demonstrated a small radiographic decrease in tumor size but experienced disease progression after three months (Vaishnavi et al. 2013)
 
III. Representative Data

1. WB of TFG-NTRK1/BaF3 expression

2. Anti-proliferation assay

Figure 2. Anti-proliferation assay of two reference compounds on the TFG-NTRK1/BaF3 Stable Cell Line


药靶模型联系方式: 华东销售经理:18240630236 全国销售经理:18066071954
诊断标准品联系方式: 华东销售经理:15000320447 华北销售经理:18131625521 华南销售经理:13484295986 华中&西南销售经理:13871580511 全国销售经理:13484295986

扫二维码

立即提交